乳腺癌患者手术前后血清中sIL－2R测定的价值  

DETERMINATION ON SERUM sIL 2R FOR PATIENT WITH BREAST CANCER

作　　者：刘爱国[1] 李同度[1] 黄伟民 高学平 

机构地区：[1]安徽省肿瘤医院

出　　处：《中国慢性病预防与控制》1996年第6期244-245,共2页Chinese Journal of Prevention and Control of Chronic Diseases

摘　　要：本文应用双ＭｃＡｂ－ＥＬＩＳＡ夹心法检测３４例乳腺癌患者手术前及术后２周、４周血清中ｓＩＬ－２Ｒ的水平，结果表明乳腺癌患者血清中ｓＩＬ－２Ｒ水平明显高于正常人及乳腺良性病变患者（Ｐ＜０．０１）。手术后２周、４周血清中ｓＩＬ－２Ｒ均有所下降，但部分Ⅲ期及Ⅳ期患者下降不明显，特别是半年内发生远处转移的２例患者，手术前后几乎无明显变化。提示：１．乳腺癌患者机体处于高度免疫抑制状态。２．手术后患者机体免疫状况得到改善，但已有转移者免疫状况无明显变化。３．手术前后ｓＩＬ－２Ｒ水平的检测可间接估计乳腺癌患者预后。34 cases of breast cancers were determined the level of serum sIL 2R in preoperative and post operative in the 2 or 4 weeks with the method of double McAbELISA.The results indicated that the level of sIL 2R of the patients was remarkably higher than the normal controls and the patients with benign breast disease( P <0.01).2 or 4 weeks after operation,the level of sIL 2R was decreased but not to be in the phase Ⅲ and Ⅳ,especially who were distant metastases in early a half of year.This suggested that 1.There was inhibitory state of immunity in the breast cancer patients;2.There was improvement of immunity in the post operative patients but not for the metastases one;3.sIL 2R could indirectly assess the prognoses for the breast cancer patients of pre and post operative.

关 键 词：乳腺癌 可溶性 白细胞介素2 受体 

分 类 号：R737.902[医药卫生—肿瘤]